Tempus’ platform builds comprehensive molecular and clinical data sets, leveraging machine learning, sequencing and artificial intelligence-assisted image recognition to offer analysis of and insights into the data.
The company will use the funds to grow operations and expand into new therapeutic areas and geographies.
Additionally, Tempus has collaboration agreements with CancerLinQ, a nonprofit subsidiary of the American Society of Clinical Oncology as well as academic medical centers and National Cancer Institute-designated cancer centers, hospital networks and physicians.
More articles on precision medicine:
Garmin expands work in cardiac health
NIH awards consortium $6.5M to create predictive models for precision medicine
Boston Children’s Hospital to sequence 3K patients’ DNA to study epilepsy, digestive disease
